Magnetic resonance tomography capabilities and limitations in managing the efficacy of treatment with biological disease modifying anti-rheumatic drugs in ankylosing spondylitis

Extensive use of magnetic resonance imaging (MRI) in clinical practice revolutionized our understanding of the pathogenesis of axis spondyloarthritis (aSpA) and treatment approaches. The use of MRI to diagnose non-radiographic aSpA is well established. At the same time, the possibility of its use for follow-up and treatment assessment is actively discussed.

Objective: To present comparative analysis of clinical and laboratory data, reflecting the activity of the disease, and analysis of MRI results in patients with ankylosing spondylitis (AS) receiving biological disease modifying anti-rheumatic drugs therapy (bDMARDs).

Patients and methods. The study included 39 patients with AS, mainly men (74.3%), 24 patients (61.5%) had late and 15 (38.5%) – advanced stage of the disease. The average age was 41.0 [34.0; 48.0] years. All patients were administered bDNARDs; inhibitors of the tumor necrosis factor α or inhibitors of interleukin 17 were drug of choice. The median of treatment duration was 1.5 [1.0; 4,5] year. All patients had sacroiliac (SI) and spinal MRI. The activity of the disease was estimated using BASDAI and ASDAS-CRP/ESR indexes, functional disorders – using the BASFI questionnaire. Results and discussion. There was no significant difference in disease activity between patients with osteitis in the SI/spine or without it: BASDAI – 4.7 [2.7; 5,5] and 4.2 [2.9; 8,1], respectively (p=0.533); ASDAS-ESR – 2.6 [2.2; 3,0] and 2.6 [2.2; 3,2], respectively (p=0.725); ASDAS-CRP – 2.5 [2.1; 3,4] and 3.1 [2.8; 3.9], respectively (p=0.172). There was no significant difference in the number of osteitis foci between group of patients who have achieved the therapeutic target (ASDAS < 2.1) and those who have not (ASDAS ≥2.1) – 1.0 [0.0; 3.5] and 1.0 [1.0; 4.0], respectively, (p=0.376), and no difference in amount of inflammatory changes – 1.0 [0.2; 1.7] and 0.1 [0.0; 1,1] cm3, respectively (p=0.124). Conclusion. The data suggests a limited MRI informative value as a method for managing the efficacy of bDMARDs treatment in patients with the advanced / late stage of the AS.

1. Rumyantseva DG, Erdes ShF. Axial spondyloarthritis: a current look at the concept and evolution of the disease. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;13(4):4-10 (In Russ.). doi:10/14412/1996-7012-2019-4-4-10

2. Bennett AN, Marzo-Ortega H, KaurPapadakis D, et al. The use of magnetic resonance imaging in axial spondyloarthritis: time to bridge the gap between radiologists and rheumatologists. J Rheumatol. 2017 Jun; 44(6):780-5. doi: 10.3899/jrheum.161337. Epub 2017 Apr 1.

3. Baraliakos X, Richter A, Feldmann D, et al. Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? Ann Rheum Dis. 2020 Nov 25; annrheumdis-2020-218669. doi: 10.1136/annrheumdis-2020-218669. Online ahead of print.

4. Chan SC, Li PH, Lee KH, et al. Diagnostic utility of whole spine and thoracic spine MRI corner inflammatory lesions in axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Nov 24;12: 1759720X20973922. doi: 10.1177/1759720X20973922. eCollection 2020.

5. Bakker PAC, Ramiro S, Ez-Zaitouni Z, et al. Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis? Arthritis Rheumatol. 2019 Mar;71(3):382-91. doi: 10.1002/art.40718. Epub 2019 Feb 6.

6. Gaidukova IZ, Rebrov AP, Korotaeva TV, et al. Remission in axial spondyloarthritis: Definition and evaluation tools (recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia»). Nauchno-Prakticheskaya Revmatologiya. 2018;56(1):10-4 (In Russ.).

7. Andreasen RA, Kristensen LE, Baraliakos X, et al. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. Arthritis Res Ther. 2020 Jul 25;22(1):177. doi: 10.1186/s13075-020-02262-4.

8. Schwartzman M, Maksymowych WP. Is there a role for MRI to establish treatment indications and effectively monitor response in patients with axial spondyloarthritis? Rheum Dis Clin North Am. 2019 Aug;45(3): 341-58. doi: 10.1016/j.rdc.2019.04.009. Epub 2019 Jun 5.

9. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi: 10.1002/acr.24025. Epub 2019 Aug 21.

10. Machado PM, Landewe R, van der Heijde D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018 Oct; 77(10):1539-40. doi: 10.1136/annrheumdis2018-213184. Epub 2018 Feb 16.

11. Erdes Sh, Smirnov AV. Diagnostic technology for inflammatory changes in the skeleton with ankylosing spondylitis according to magnetic resonance imaging. NauchnoPrakticheskaya Revmatologiya. 2019;57(6): 678-84 (In Russ.).

12. Madari Q, Sepriano A, Ramiro S, et al. 5-year follow- up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the Desir cohort. RMD Open. 2020 Feb;6(1):e001093. doi: 10.1136/rmdopen-2019-001093.

13. Huang Y, Chen Y, Liu T, et al. Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A metaanalysis. PLoS One. 2020 Dec 31;15(12):e0244788. doi: 10.1371/journal.pone.0244788. eCollection 2020.

14. Erdes Sh, Rumyantseva DG, Smirnov AV, et al. Disease activity and two-year sacroiliac joint changes according to instrumental study findings in a CoRSAr cohort of patients with early axial spondyloarthritis. NauchnoPrakticheskaya Revmatologiya. 2019;57(2): 186-90 (In Russ.).

15. Krabbe S, Eshed I, S∅rensen IJ, et al. Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis. Rheumatology (Oxford). 2020 Nov 1;59(11): 3358-68. doi: 10.1093/rheumatology/keaa153.

16. Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripher al spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi:10.1136/annrheumdis-2017-211734

17. Akulova AI, Dorogoikina KD, Gaydukova IZ, et al. Quality of life in spondyloarthritis patients receiving biological therapy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;13(4):36-40. (In Russ.). doi:10.14412/1996-7012-2019-4-36-40